Nuclear localized p70S6K maintain cancer stem-like properties by modulating RPA3 activity in osteosarcoma
Cellular Signalling · 2026
DOI: 10.1016/j.cellsig.2026.112804 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2026. Verfasst von Jing Zhou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hubei Provincial Key Laboratory of Occurrence and Intervention of Kidney Diseases, Hubei Provincial Engineering Research Center of Immunotherapy Drug…. Hauptthemen laut MEDLINE: Osteosarcoma, Ribosomal Protein S6 Kinases, 70-kDa, Neoplastic Stem Cells, Cell Nucleus. Die Arbeit nennt 55 Literaturangaben. Gefördert von: Health Commission of Hubei Province, Hubei Provincial Department of Education, Natural Science Foundation of Hubei Province.
Abstract (Originalsprache)
Cancer stem-like cells (CSCs) are believed to be a pivotal contributor to therapy failure in various cancers including osteosarcoma. Targeting CSCs is a promising strategy to overcome chemoresistance and improve outcomes in osteosarcoma treatment. Besides the conventionally studied cytoplasmic p70 ribosomal protein S6 kinase (p70S6K), a well-established oncogenic driver, nuclear localized p70S6K is also observed to be related with worse prognosis in various cancers. However, there remains a considerable gap in the studies on the roles of nuclear localized p70S6K in cancer development. Here, we present a novel nuclear function of p70S6K in driving acquisition of CSC properties in osteosarcoma cells by physically interacting with replication protein A3 (RPA3), which is highly expressed in osteosarcoma CSCs subpopulation revealed by single-cell transcriptomics analyses, and modulating its single-strand DNA-binding activity. Importantly, blockage of p70S6K-RPA axis using pharmacological inhibitors remarkably suppresses the tumor growth of osteosarcoma. This study first reveals the impact and underlying mechanism of nuclear localized p70S6K and RPA3 in promoting CSCs maintenance, and highlights the nuclear p70S6K-RPA3 pathway as a promising CSC-based therapeutic target for osteosarcoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hubei Provincial Key Laboratory of Occurrence and Intervention of Kidney Diseases, Hubei Provincial Engineering Research Center of Immunotherapy Drugs for Renal Tumors, Faculty of Medicine, Collaborative Technology of A…
- Breast Cancer Center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National key clinical specialty discipline construction program, Hubei Provincial Clinical Research Cen…
- State Key Laboratory of Biocatalysis and Enzyme Engineering, Stem Cells and Tissue Engineering Manufacture Center, School of Life Sciences, Hubei University, Wuhan, China. Electronic address: gaowj@hubu.edu.cn.
Förderung
- Health Commission of Hubei Province
- Hubei Provincial Department of Education
- Natural Science Foundation of Hubei Province
- Hubei Polytechnic University
Zitieren
APA
Zhou, J., Li, B., Gao, Q., Ye, Z., Zeng, X., Zhou, Y., Wang, Z., Zou, L., Zheng, Y., Wang, J., & Gao, W. (2026). Nuclear localized p70S6K maintain cancer stem-like properties by modulating RPA3 activity in osteosarcoma. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2026.112804
Vancouver
Zhou J, Li B, Gao Q, Ye Z, Zeng X, Zhou Y, et al. Nuclear localized p70S6K maintain cancer stem-like properties by modulating RPA3 activity in osteosarcoma. Cellular Signalling. 2026. doi:10.1016/j.cellsig.2026.112804
BibTeX
@article{Zhou2026,
author = {Zhou, Jing and Li, Bo and Gao, Qi and Ye, Zijian and Zeng, Xiaobo and Zhou, Yuan and Wang, Zhiyuan and Zou, Limei and Zheng, Yuanmei and Wang, Jingru and Gao, Weijie},
title = {Nuclear localized p70S6K maintain cancer stem-like properties by modulating RPA3 activity in osteosarcoma},
journal = {Cellular Signalling},
year = {2026},
doi = {10.1016/j.cellsig.2026.112804}
}
EUVIMED